BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be ...

TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001)– For ...

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that ...

Analyst Paul Choi of Goldman Sachs maintained a Buy rating on Ascendis Pharma (ASND – Research Report), boosting the price target to ...

AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...

In a notable update, Cantor Fitzgerald has reiterated its “Overweight” rating on Ascendis Pharma’s stock. The analyst’s price target remains set at $170, reflecting optimism about the company’s future ...

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.

American depositary receipts of Ascendis Pharma A/S rose 15% on topline data from a trial of TransCon CNP, a potential treatment for children with achondroplasia. ADRs were trading around $137. ADRs ...